• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cardio Diagnostics Holdings Inc.

    4/8/25 4:30:37 PM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CDIO alert in real time by email
    S-8 1 cdio_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on April 8, 2025

     

    Registration No. 333-_______

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    ____________________________

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    ____________________________

    CARDIO DIAGNOSTICS HOLDINGS, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   6770   87-0925574
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification No.)

     

    311 W. Superior St., Ste. 444

    Chicago, IL 60654

    Telephone: (855) 226-9991
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan

    (Full Title of the Plan)

    ____________________________

    Meeshanthini V. Dogan, Ph.D.
    Chief Executive Officer
    Cardio Diagnostics Holdings, Inc.

    311 W. Superior St., Ste. 444

    Chicago, IL 60654
    Telephone: (855) 226-9991
    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    ____________________________

    Copies to:

    P. Rupert Russell, Esq.
    Shartsis Friese LLP
    425 Market Street, 11th Floor
    San Francisco, CA 94105
    (415) 421-6500

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

        Large accelerated filer   ☐   Accelerated filer   ☐
        Non- accelerated filer   ☒   Smaller reporting company   ☒
                Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed with the Securities and Exchange Commission (the “Commission”) by Cardio Diagnostics Holdings, Inc. (the “Company” or the “Registrant”) for the purpose of registering 2,871,638 additional shares of the Company’s common stock, par value of $0.00001 per share (the “Common Stock”), issuable under the Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan (the “2022 Plan”), pursuant to the automatic share reserve increase provision set forth in Section 5(a) of the 2022 Plan.

    Pursuant to the Company’s Registration Statement on Form S-8 (File No 333-270752) filed by the Registrant on March 22, 2023 (the “Prior Registration Statement”), the Registrant previously initially registered an aggregate of 3,265,516 shares of Common Stock under the 2022 Plan. Pursuant to the Company’s Registration Statement on Form S-8 (File No 333-278962) filed by the Registrant on April 26, 2024 (the “Prior Additional Registration Statement” and together with the Prior Registration Statement, the “Prior Registration Statements”), the Registrant previously additionally registered an aggregate of 1,060,458 shares of Common Stock under the 2022 Plan. The additional shares of Common Stock being registered by this Registration Statement are of the same class as those securities registered on the Prior Registration Statements. The contents of the Prior Registration Statements, together with all exhibits filed therewith or incorporated therein by reference to the extent not otherwise amended or superseded by the contents hereof or otherwise, are incorporated herein by reference in accordance with General Instruction E to Form S-8.

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the 2022 Plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act. Such documents are not required to be, and are not, filed with the Commission, either as part of this Registration Statement or as a prospectus or prospectus supplement pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II hereof, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    The Company will provide a written statement to participants advising them of the availability without charge, upon written or oral request, of the documents incorporated by reference in Item 3 of Part II hereof and including the statement in the preceding sentence. The written statement to all participants will indicate the availability without charge, upon written or oral request, of other documents required to be delivered pursuant to Rule 428(b) and will include the address and telephone number to which the request is to be directed.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

      Item 3. Incorporation of Documents by Reference.

    The following documents, filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) are incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

    • The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 20, 2025 (the “Annual Report”).

     
     

    In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are “furnished” and not “filed” in accordance with the rules of the Commission, shall not be deemed to be incorporated by reference in this Registration Statement.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

      Item 8. Exhibits.

    The following exhibits are filed as part of this Registration Statement:

            Incorporation by Reference
    Exhibit Number   Description   Form   Exhibit   Filing
    Date
                     
    4.1   Third Amended and Restated Certificate of Incorporation of Cardio Diagnostics Holdings, Inc., dated May 30, 2023   8-K   3.1   5/30/23
    4.2   By-laws   S-1   3.3   10/19/21
    4.3   Description of Securities   10-K   4.5   4/1/24
    5.1*   Opinion of Shartsis Friese, LLP            
    23.1*   Consent of Prager Metis CPAs LLC, independent registered public accounting firm            
    99.1   Cardio Diagnostics Holdings, Inc. 2022 Equity Incentive Plan and related forms of agreements   10-K   10.4   4/1/24
    107*   Filing Fee Table            
                     

    __________

    * Filed herewith

      Item 9. Undertakings.

     

    1.       The undersigned Registrant hereby undertakes:

    (a)       To file, during any period in which offers or sales are being made, a post-effective amendment to the Registration Statement:

    (i)       to include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)       to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof), which individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     
     

    (iii)       to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; provided, however, that paragraphs (1)(a)(i) and (1)(a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with, or furnished to, the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (b)       That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)       To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2.       The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3.       Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     
     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Chicago, Illinois, on the 8th day of April, 2025. 

      CARDIO DIAGNOSTICS HOLDINGS, INC.
       
       By: /s/ Meeshanthini V. Dogan
        Meeshanthini V. Dogan
    Chief Executive Officer

     

    POWER OF ATTORNEY

    KNOW ALL MEN BY THESE PRESENTS, that of the undersigned constitutes and appoints Meeshanthini V. Dogan and Elisa Luqman, and each of them, her true and lawful attorney-in-fact and agent, with full power of substitution and revocation, for her and in her name, place and stead, in any and all capacities, to execute any or all amendments including any post-effective amendments and supplements to this Registration Statement, and any additional Registration Statement filed pursuant to Rule 462(b), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

             
    Name   Position   Date
         

    /s/ Meeshanthini V. Dogan

    Meeshanthini V. Dogan

     

    Chief Executive Officer, Director

    (principal executive officer)

      April 8, 2025
         

    /s/ Elisa Luqman

    Elisa Luqman

     

    Chief Financial Officer

    (principal financial officer and principal accounting officer)

      April 8, 2025
         

    /s/ Warren Hosseinion

      Director, Chair   April 8, 2025
    Warren Hosseinion    
         

    /s/ James Intrater

    James Intrater

      Director   April 8, 2025
         

    /s/ Peter K. Fung

    Peter K. Fung

      Director   April 8, 2025
         

    /s/ Wendy J. Betts

    Wendy J. Betts

      Director   April 8, 2025
         

    /s/ Robert Philibert

    Robert Philibert

     

      Director   April 8, 2025

    /s/ Paul Burton

      Director   April 8, 2025

    Paul Burton

     

           

      

     

     

    Get the next $CDIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CDIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

      Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors. The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company's continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, makin

      1/24/24 8:31:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors

      Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical

      12/21/23 9:21:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CDIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CDIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CDIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CDIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Fung Peter K

      4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      4/1/25 1:19:48 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Betts Wendy J

      4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      4/1/25 1:17:06 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Burton Paul Frederick

      4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      4/1/25 12:54:12 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Cardio Diagnostics Holdings Inc. (Amendment)

      SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)

      5/8/24 2:22:56 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cardio Diagnostics Secures Japanese Patent for AI-Driven Cardiovascular Disease Detection Technology

      Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced that the Japan Patent Office has issued a patent for another set of biomarkers in the company's intellectual property portfolio. The patent, titled "Compositions and Methods for Detecting Predisposition to Cardiovascular Disease," (Japanese Patent No. 7672192) is exclusively licensed to Cardio Diagnostics from the University of Iowa Research Foundation (UIRF) and names Cardio Diagnostics' founders Meesha Dogan, Ph.D., Chief Executive Officer, and Robert Philibert, MD, Ph.D., Chief Medical Officer, as inventors. The Japanese patent further strengthen

      6/10/25 8:35:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cardio Diagnostics Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price

      Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a pioneer in AI-powered precision cardiovascular medicine, today announced that on May 28, 2025, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Requirement") for continued listing on The Nasdaq Capital Market. This was disclosed in the Company's Current Report on Form 8-K filed on May 28, 2025. The Nasdaq staff made this determination of compliance af

      5/29/25 8:35:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cardio Diagnostics Broadens Access to Precision Cardiovascular Care with New Practice Partnerships Across U.S. Mainland and Puerto Rico

      Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a pioneer in AI-powered precision cardiovascular medicine, today announced the continued expansion of its reach with a new cohort of healthcare practices across the United States now offering its innovative clinical blood tests, Epi+Gen CHD™ and PrecisionCHD™. This group of adopters spans a wide range of care models - from concierge and direct primary care to functional and integrative medicine, demonstrating the growing appetite for proactive, personalized cardiovascular care. These latest adopters are primarily independent practices deeply committed to modernizing the patient experience and championing heart disease prevention and early d

      5/20/25 8:35:00 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: Chief Technology Officer Dogan Timur bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

      4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      10/9/24 1:18:30 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: Chief Executive Officer Dogan Meeshanthini bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

      4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      10/8/24 10:42:31 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: Chief Executive Officer Dogan Meeshanthini bought $20,000 worth of shares (68,965 units at $0.29) (SEC Form 4)

      4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)

      10/7/24 11:29:46 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CDIO
    SEC Filings

    See more
    • Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

      5/28/25 4:30:25 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.

      10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

      5/15/25 4:20:23 PM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

      5/13/25 8:00:25 AM ET
      $CDIO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care